Zynerba Pharmaceuticals, Inc

(NASDAQ:ZYNE)

Latest On Zynerba Pharmaceuticals, Inc (ZYNE):

Date/Time Type Description Signal Details
2023-05-15 16:58 ESTNewsZynerba Pharmaceuticals GAAP EPS of -$0.21 misses by $0.02N/A
2023-03-28 14:10 ESTNewsZynerba Pharmaceuticals GAAP EPS of -$0.18 in-lineN/A
2023-03-13 21:08 ESTNewsZynerba Pharma says not holding cash deposits or securities at Silicon Valley BankN/A
2023-01-11 16:14 ESTNewsZynerba Pharma rises 6% on positive data from Fragile X syndrome treatment trialN/A
2022-12-21 13:11 ESTNewsZynerba delaying release of late-stage top-line results for Fragile X syndrome candidateN/A
2022-11-15 10:23 ESTNewsZynerba rises on orphan drug status for cannabidiol Zygel for 22q11.2 deletion syndrome in EUN/A
2022-11-14 17:45 ESTNewsZynerba Pharmaceuticals GAAP EPS of -$0.20 beats by $0.03N/A
2022-11-03 01:21 ESTNewsZynerba gets US patent for cannabidiol Zygel to treat 22q11.2 Deletion SyndromeN/A
2022-10-06 18:44 ESTNewsZynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndromeN/A
2022-08-10 07:56 ESTNewsZynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01N/A
2022-07-22 07:36 ESTNewsZynerba inks equity funding contract of up to $20M with Lincoln Park CapitalN/A
2022-06-22 10:22 ESTNewsZynerba stock rises as CBD gel improves rare disorder symptoms in trial; autism program deferredN/A
2022-03-01 15:49 ESTNewsZynerba Pharmaceuticals GAAP EPS of -$0.22 beats by $0.04N/A
2022-02-28 22:18 ESTNewsZynerba Pharma gets orphan drug designation from European Commission for Zygel in FXSN/A
2022-01-04 20:47 ESTNewsZynerba pushes back development of Zygel in a group of epilepsiesN/A
2021-11-22 13:25 ESTNewsZynerba Pharma pops 4% after securing new European patent for Zygel CBD gelN/A
2021-11-15 15:43 ESTNewsZynerba Pharmaceuticals EPS misses by $0.01N/A
2021-11-11 16:10 ESTNewsRevisiting Zynerba PharmaceuticalsN/A
2021-09-22 11:45 ESTNewsZynerba Pharmaceuticals (ZYNE) Investor presentation - SlideshowN/A
2021-09-09 15:03 ESTNewsZynerba Pharmaceuticals posts longer term data from Zygel autism studyN/A
2021-09-07 23:24 ESTNewsZynerba highlights results from mid-stage Zygel epilepsy studyN/A
2021-08-09 18:06 ESTNewsZynerba Pharmaceuticals EPS misses by $0.05N/A
2021-07-22 09:44 ESTNewsZynerba Pharmaceuticals (ZYNE) Presents At HealthVirtual Conference - SlideshowN/A
2021-05-06 02:17 ESTNewsZynerba receives FDA guidance for Phase 3 trial design for Zygel in rare genetic disorderN/A
2021-04-13 22:52 ESTNewsZynerba: Repeated Trial Failures, Some Post Hoc SuccessN/A
2021-03-12 05:04 ESTFinancialsCompany financials have been released.Neutral
2021-03-11 01:10 ESTEarnings EstimateAn EPS average of -$1.13 is estimated for the 2022 year.Sell
2021-03-11 01:10 ESTEarnings EstimateAn EPS average of -$0.23 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-11 01:10 ESTAnalyst RatingThe Analyst Target Price has increased from $7.25 to $7.29.Buy
2021-03-10 22:03 ESTNewsZynerba Pharmaceuticals EPS in-lineN/A
2021-02-15 12:43 ESTAnalyst RatingThe Analyst Target Price has decreased from $7.42 to $7.25.Neutral
2021-02-07 02:02 ESTNewsMarijuana as medicine: the other cannabinoid pharma playersN/A
2021-02-04 04:28 ESTNewsZogenix, Zynerba jump on positive read through from GW Pharma/Jazz (update)N/A
2021-01-26 00:28 ESTNewsZeroing In On Zynerba PharmaceuticalsN/A
2020-12-22 13:13 ESTAnalyst RatingThe Analyst Target Price has decreased from $7.92 to $7.42.Neutral
2020-12-21 13:23 ESTAnalyst RatingThe Analyst Target Price has decreased from $9.67 to $7.92.Neutral
2020-12-18 13:35 ESTAnalyst RatingThe Analyst Target Price has decreased from $10 to $9.67.Neutral
2020-12-18 02:52 ESTNewsZynerba expects to launch new Zygel trial before end of 2021, shares down 10%N/A
2020-12-17 08:48 ESTNewsZynerba Pharma shares slip 10% on Zygel update in Fragile X syndromeN/A
2020-11-26 22:12 ESTFinancialsCompany financials have been released.Neutral
2020-11-21 08:37 ESTNewsSeeking Alpha Catalyst WatchN/A
2020-11-11 05:29 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 13:34 ESTEarnings EstimateAn EPS average of -$0.38 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-09 23:47 ESTNewsZynerba Pharmaceuticals EPS beats by $0.12N/A
2020-11-08 01:23 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:39 ESTFinancialsCompany financials have been released.Neutral
2020-11-01 06:22 ESTNewsZynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite SetbackN/A
2020-10-16 06:20 ESTNewsNew data shows Zynerba's ZYN002 positive effect in autism studyN/A
2020-09-26 14:40 ESTFinancialsCompany financials have been released.Neutral
2020-09-25 04:38 ESTNewsZynerba Pharmaceuticals - Whether They've Cracked The Code For Fully Methylated FX Syndrome PatientsN/A

About Zynerba Pharmaceuticals, Inc (ZYNE):

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

ZYNE Quotes by TradingView

See Advanced Chart

General

  • Name Zynerba Pharmaceuticals, Inc
  • Symbol ZYNE
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 26
  • Fiscal Year EndDecember
  • IPO Date2015-08-05
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://zynerba.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 1152.69
  • Price/Book (Most Recent Quarter) 3.51
  • Enterprise Value Revenue 397.61
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.02
  • Next Year EPS Estimate -$1.13
  • Next Quarter EPS Estimate -$0.32
  • Return on Assets -40%
  • Return on Equity -76%
  • Revenue 86000
  • Earnings Per Share -$1.89
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 214.92 million
  • EBITDA -36895716
  • Analyst Target Price $7.29
  • Book Value Per Share $2.02
View More

Share Statistics

  • Shares Outstanding 41.25 million
  • Shares Float 40.16 million
  • % Held by Insiders 711%
  • % Held by Institutions 22.03%
  • Shares Short 2.99 million
  • Shares Short Prior Month 3.2 million
  • Short Ratio 0.25
  • Short % of Float 11%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 2.82
  • 52 Week High $9
  • 52 Week Low $3.11
  • 50 Day Moving Average 4.92
  • 200 Day Moving Average 4.01
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Zynerba Pharmaceuticals, Inc (ZYNE) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Zynerba Pharmaceuticals, Inc (ZYNE) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-10$N/A-$0.33-$0.33-0.43%
2020-09-302020-11-09$N/A-$0.31-$0.4328.39%
2020-06-302020-08-10$N/A-$0.78-$0.45-74.46%
2020-03-312020-05-11$N/A-$0.53-$0.50-6.62%
2019-12-312020-03-10$N/A-$0.46-$0.519.29%
2019-09-302019-11-06$N/A-$0.08-$0.5284.66%
2019-06-302019-08-06$N/A-$0.50-$0.49-1.52%
2019-03-312019-05-08$N/A-$0.47-$0.493.75%
2018-12-312019-03-11$86000-$0.44-$0.6633%
2018-09-302018-11-08$N/A-$0.47-$0.6729.85%
2018-06-302018-08-02$N/A-$0.89-$0.74-20.27%
2018-03-312018-05-08$N/A-$0.91-$0.63-45.02%
2017-12-312018-03-12$N/A-$0.60-$0.600.28%
2017-09-302017-11-14$N/A-$0.63-$0.60-4.56%
2017-06-302017-08-01$N/A-$0.64-$0.59-8.47%
2017-03-312017-05-09$N/A-$0.60-$0.56-7.62%
2016-12-312017-03-27$7250-$0.71-$0.66-6.93%
2016-09-302016-11-14$N/A-$0.67-$0.55-21.82%
2016-06-302016-08-11$-7000-$0.70-$0.50-41.41%
2016-03-312016-05-12$7000-$0.49-$0.5611.71%
2015-12-312016-03-14$49000-$0.62-$0.50-24%
2015-09-302015-11-11$200000-$0.66-$0.38-73.68%
2015-06-302015-08-05$15000-$0.18

Zynerba Pharmaceuticals, Inc (ZYNE) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Zynerba Pharmaceuticals, Inc (ZYNE) Chart:

Zynerba Pharmaceuticals, Inc (ZYNE) News:

Below you will find a list of latest news for Zynerba Pharmaceuticals, Inc (ZYNE) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Zynerba Pharmaceuticals, Inc (ZYNE) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest ZYNE Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST100$1.015
Jun 13, 2022 7:59 PM EST2$1.015
Jun 13, 2022 7:59 PM EST2$1.015
Jun 13, 2022 7:59 PM EST2$1.015
Jun 13, 2022 7:59 PM EST1$1.015

Zynerba Pharmaceuticals, Inc (ZYNE) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920078403/0001104659-20-078403-index.htm
2019-08-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1621443/000000000019012187/0000000000-19-012187-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1621443/000083423720008152/0000834237-20-008152-index.htm
2020-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1621443/000083423720009919/0000834237-20-009919-index.htm
2019-04-25DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1621443/000104746919002558/0001047469-19-002558-index.htm
2018-06-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465918038780/0001104659-18-038780-index.htm
2018-07-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465918043916/0001104659-18-043916-index.htm
2018-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465918044210/0001104659-18-044210-index.htm
2018-07-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465918044790/0001104659-18-044790-index.htm
2018-07-19424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1621443/000110465918046019/0001104659-18-046019-index.htm
2018-07-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465918046020/0001104659-18-046020-index.htm
2018-07-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1621443/000110465918046315/0001104659-18-046315-index.htm
2018-07-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465918046317/0001104659-18-046317-index.htm
2018-08-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465918048964/0001104659-18-048964-index.htm
2018-09-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465918055197/0001104659-18-055197-index.htm
2018-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465918059546/0001104659-18-059546-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465918066802/0001104659-18-066802-index.htm
2018-12-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465918072585/0001104659-18-072585-index.htm
2018-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465918073196/0001104659-18-073196-index.htm
2019-01-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465919000679/0001104659-19-000679-index.htm
2019-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465919009430/0001104659-19-009430-index.htm
2019-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465919010499/0001104659-19-010499-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465919013241/0001104659-19-013241-index.htm
2019-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465919013709/0001104659-19-013709-index.htm
2019-03-11S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1621443/000110465919013754/0001104659-19-013754-index.htm
2019-04-25DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1621443/000110465919023594/0001104659-19-023594-index.htm
2019-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465919026966/0001104659-19-026966-index.htm
2019-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465919027154/0001104659-19-027154-index.htm
2019-05-06DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1621443/000110465919027157/0001104659-19-027157-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465919027667/0001104659-19-027667-index.htm
2019-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465919032197/0001104659-19-032197-index.htm
2019-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465919035052/0001104659-19-035052-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465919044130/0001104659-19-044130-index.htm
2019-08-06S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1621443/000110465919044150/0001104659-19-044150-index.htm
2019-08-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1621443/000110465919045135/0001104659-19-045135-index.htm
2019-08-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465919048256/0001104659-19-048256-index.htm
2019-08-30424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1621443/000110465919048268/0001104659-19-048268-index.htm
2019-09-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465919050481/0001104659-19-050481-index.htm
2019-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465919051099/0001104659-19-051099-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465919060256/0001104659-19-060256-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920003213/0001104659-20-003213-index.htm
2020-02-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920009482/0001104659-20-009482-index.htm
2020-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1621443/000110465920016335/0001104659-20-016335-index.htm
2020-02-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920024469/0001104659-20-024469-index.htm
2020-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920025024/0001104659-20-025024-index.htm
2020-03-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920028362/0001104659-20-028362-index.htm
2020-03-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920030972/0001104659-20-030972-index.htm
2020-03-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1621443/000110465920031380/0001104659-20-031380-index.htm
2020-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920046587/0001104659-20-046587-index.htm
2020-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1621443/000110465920050049/0001104659-20-050049-index.htm
2020-04-23DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1621443/000110465920050053/0001104659-20-050053-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920059089/0001104659-20-059089-index.htm
2020-05-21DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1621443/000110465920064527/0001104659-20-064527-index.htm
2020-05-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920065620/0001104659-20-065620-index.htm
2020-05-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920066085/0001104659-20-066085-index.htm
2020-06-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920068652/0001104659-20-068652-index.htm
2020-06-028-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920068926/0001104659-20-068926-index.htm
2020-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920072407/0001104659-20-072407-index.htm
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920078403/0001104659-20-078403-index.htm
2020-07-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920085391/0001104659-20-085391-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920092358/0001104659-20-092358-index.htm
2020-09-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920104585/0001104659-20-104585-index.htm
2020-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920106099/0001104659-20-106099-index.htm
2020-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621443/000110465920115292/0001104659-20-115292-index.htm
2018-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248218000271/0001192482-18-000271-index.htm
2018-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248218000272/0001192482-18-000272-index.htm
2018-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248218000273/0001192482-18-000273-index.htm
2018-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248218000274/0001192482-18-000274-index.htm
2018-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248218000275/0001192482-18-000275-index.htm
2018-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248218000276/0001192482-18-000276-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248218000330/0001192482-18-000330-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248218000331/0001192482-18-000331-index.htm
2018-08-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248218000383/0001192482-18-000383-index.htm
2018-08-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248218000384/0001192482-18-000384-index.htm
2018-08-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248218000385/0001192482-18-000385-index.htm
2018-08-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248218000386/0001192482-18-000386-index.htm
2018-08-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248218000409/0001192482-18-000409-index.htm
2018-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248218000453/0001192482-18-000453-index.htm
2018-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248218000455/0001192482-18-000455-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000007/0001192482-19-000007-index.htm
2019-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000047/0001192482-19-000047-index.htm
2019-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000048/0001192482-19-000048-index.htm
2019-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000049/0001192482-19-000049-index.htm
2019-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000050/0001192482-19-000050-index.htm
2019-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000051/0001192482-19-000051-index.htm
2019-01-304/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000063/0001192482-19-000063-index.htm
2019-02-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000098/0001192482-19-000098-index.htm
2019-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000100/0001192482-19-000100-index.htm
2019-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000184/0001192482-19-000184-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000280/0001192482-19-000280-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000282/0001192482-19-000282-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000284/0001192482-19-000284-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000286/0001192482-19-000286-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000288/0001192482-19-000288-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000290/0001192482-19-000290-index.htm
2019-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000310/0001192482-19-000310-index.htm
2019-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248219000364/0001192482-19-000364-index.htm
2020-02-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248220000087/0001192482-20-000087-index.htm
2020-02-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248220000089/0001192482-20-000089-index.htm
2020-02-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248220000091/0001192482-20-000091-index.htm
2020-02-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248220000093/0001192482-20-000093-index.htm
2020-02-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248220000095/0001192482-20-000095-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248220000463/0001192482-20-000463-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248220000465/0001192482-20-000465-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248220000467/0001192482-20-000467-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248220000469/0001192482-20-000469-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248220000471/0001192482-20-000471-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621443/000119248220000473/0001192482-20-000473-index.htm
2019-12-02SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1621443/000121390019025094/0001213900-19-025094-index.htm
2020-05-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1621443/000121390020011593/0001213900-20-011593-index.htm
2019-01-29SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1621443/000149315219001070/0001493152-19-001070-index.htm
2018-08-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1621443/000155837018006158/0001558370-18-006158-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1621443/000155837018008905/0001558370-18-008905-index.htm
2019-03-1110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1621443/000155837019001742/0001558370-19-001742-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1621443/000155837019004373/0001558370-19-004373-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1621443/000155837019007148/0001558370-19-007148-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1621443/000155837019010074/0001558370-19-010074-index.htm
2020-03-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1621443/000155837020002280/0001558370-20-002280-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1621443/000155837020006117/0001558370-20-006117-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1621443/000155837020010072/0001558370-20-010072-index.htm
2019-01-15SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1621443/000161577419000650/0001615774-19-000650-index.htm
2019-06-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1621443/000161577419009100/0001615774-19-009100-index.htm
2019-08-13EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1621443/999999999519001874/9999999995-19-001874-index.htm

Zynerba Pharmaceuticals, Inc (ZYNE) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Zynerba Pharmaceuticals, Inc (ZYNE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 711%
Institutional Ownership: 2203%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-08-06Terri B SebreePresidentBuy3,800.005.7922,013.40182,546.00https://www.sec.gov/Archives/edgar/data/1621443/000119248218000384/0001192482-18-000384-index.htm
2019-01-24Terri B SebreePresidentBuy3,600.00186,146.00https://www.sec.gov/Archives/edgar/data/1621443/000119248219000050/0001192482-19-000050-index.htm
2018-08-06James E FickenscherChief Financial OfficerBuy8,518.005.9750,842.2420,718.00https://www.sec.gov/Archives/edgar/data/1621443/000119248218000383/0001192482-18-000383-index.htm
2018-08-06ARMANDO ANIDOChairman & Chief Exec. OfficerBuy15,000.005.9689,422.50352,512.00https://www.sec.gov/Archives/edgar/data/1621443/000119248218000386/0001192482-18-000386-index.htm
2018-08-06Suzanne M. HanlonSec, VP & General CounselBuy3,800.005.8022,047.6043,693.00https://www.sec.gov/Archives/edgar/data/1621443/000119248218000385/0001192482-18-000385-index.htm
2018-08-22John P. ButlerDirectorBuy5,000.006.4332,153.005,000.00https://www.sec.gov/Archives/edgar/data/1621443/000119248218000409/0001192482-18-000409-index.htm